Sign in
Facet browsing currently unavailable
Page 1 of 179 results
Sort by: relevance publication year
|
ACCELERATING THE DEVELOPMENT OF NOVEL ANTIBODY-DRUG CONJUGATES THROUGH SITE-SPECIFIC CONJUGATION METHODS JOURNAL ARTICLE published 24 July 2023 in Antibody Therapeutics |
|
3H-3000, AN FGFR2B-SPECIFIC MONOCLONAL ANTIBODY, SHOWS SUPERIOR TUMOR KILLING IN VIVO JOURNAL ARTICLE published 24 July 2023 in Antibody Therapeutics |
|
REVOLUTIONIZING ANTIBODY DISCOVERY INDUSTRY WITH HIGHLY EFFICIENT AND ACCURATE AI-BASED EPITOPE-SPECIFIC ANTIBODY DE NOVO DESIGN WORKFLOW JOURNAL ARTICLE published 24 July 2023 in Antibody Therapeutics |
|
CAMEL NANOBODIES NEUTRALIZE SARS-COV-2 VARIANTS JOURNAL ARTICLE published 24 July 2023 in Antibody Therapeutics |
|
GENERATION OF NOVEL ANTIBODY CANDIDATES USING TRANSFORMER AND GAN-BASED DEEP LEARNING ARTIFICIAL INTELLIGENCE JOURNAL ARTICLE published 24 July 2023 in Antibody Therapeutics |
|
Expert’s views and perspectives: an interview with distinguished investigator Dr. Ira Pastan at the National Cancer Institute at NIH JOURNAL ARTICLE published 25 July 2020 in Antibody Therapeutics |
|
The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective JOURNAL ARTICLE published 1 January 2019 in Antibody Therapeutics Research funded by Cancer Prevention and Research Institute of Texas (RP150551) | Welch Foundation (AU-0042-20030616) |
|
Rapid exploration of the epitope coverage produced by an Ebola survivor to guide the discovery of therapeutic antibody cocktails JOURNAL ARTICLE published 25 July 2020 in Antibody Therapeutics |
|
SARS-CoV-2 receptor-binding mutations and antibody contact sites JOURNAL ARTICLE published 19 July 2021 in Antibody Therapeutics Research funded by Precision Medicine Initiative (PRMF2020-006) |
|
Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies JOURNAL ARTICLE published 1 January 2019 in Antibody Therapeutics Research funded by U.S. Department of Defense (W81XWH-12-1-0548) |
|
Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth JOURNAL ARTICLE published 13 April 2022 in Antibody Therapeutics |
|
Design of a chimeric ACE-2/Fc-silent fusion protein with ultrahigh affinity and neutralizing capacity for SARS-CoV-2 variants JOURNAL ARTICLE published 18 January 2023 in Antibody Therapeutics |
|
Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential JOURNAL ARTICLE published 28 March 2024 in Antibody Therapeutics |
|
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate JOURNAL ARTICLE published 28 March 2024 in Antibody Therapeutics Research funded by National Key R&D Program of China (2019YFA0904400) | National Natural Science Foundation of China (32270984) | Science and Technology Commission of Shanghai Municipality (23XD1400800) | Shanghai Municipal Health Commission (GWVI-11.2-YQ46) |
|
Antibody conjugation and formulation JOURNAL ARTICLE published 1 January 2019 in Antibody Therapeutics |
|
Insights into CD47/SIRPα axis-targeting tumor immunotherapy JOURNAL ARTICLE published 17 September 2018 in Antibody Therapeutics Research funded by National Key Basic Research Program of China (2015CB931800) | National Natural Science Foundation of China (81573332,81773620) | Shanghai Science and Technology Funds (18431902800) |
|
Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma JOURNAL ARTICLE published 31 August 2018 in Antibody Therapeutics Research funded by Cancer Research Foundation (BC008753) |
|
Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal JOURNAL ARTICLE published 18 January 2023 in Antibody Therapeutics |
|
Novel development strategies and challenges for anti-Her2 antibody-drug conjugates JOURNAL ARTICLE published 1 January 2022 in Antibody Therapeutics Research funded by Open Project of Shandong Collaborative Innovation Center for Antibody Drug (CIC-AD1803) | Chinese Postdoctoral Science Foundation (2020 M672136,2019 M662443) |
|
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2 JOURNAL ARTICLE published 3 October 2023 in Antibody Therapeutics Research funded by Horizon 2020 (899670) | European Research Council (834631) | EPSRC Future Vaccine Manufacturing and Research Hub (EP/R013764/1) | EPSRC (EP/M022609/1) | MRC (MR/V027506/1,MR/R020566/1,MR/V027506/1) | United States Food and Drug Administration (HHSF223201510104C) | European Research Council (294852) | University of Bristol (BB/L01386X/1) | BBSRC (BB/R000484/1) | Wellcome Trust (221708/Z/20/Z,206181/Z/17/Z,202904/Z/16/Z) |